Wird geladen...
Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials
The primary objective of phase I oncology trials is to find the maximum tolerated dose (MTD). The 3+3 design is easy to implement but performs poorly in finding the MTD. A newer design, such as the modified toxicity probability interval (mTPI) design, provides better accuracy to identify the MTD but...
Gespeichert in:
| Veröffentlicht in: | Clin Cancer Res |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2017
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5554436/ https://ncbi.nlm.nih.gov/pubmed/28546227 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-0220 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|